

USSN: 10/075,715
Attorney Docket No.: 1059.00073

CLAIMS:

1. (Currently amended) A method of affecting promoting neurogenesis comprising the step of:

administering a therapeutic amount of a therapeutic compound for increasing levels of cGMP to a patient in need of neurogenesis promotion post stroke wherein increased levels of cGMP result in promote neurogenesis.

2. (Currently amended) A compound for affecting promoting neurogenesis comprising an effective amount of a therapeutic compound selected from the group of phosphodiesterase inhibitors, L-arginine, sildenafil, and atorvastatin that increases levels of cGMP, sufficient to affect promote neurogenesis, wherein increased levels of cGMP result in promote neurogenesis.

3. (Currently amended) A neurogenesis affector promoter comprising a therapeutic compound in a pharmaceutically acceptable carrier that increases levels of cGMP, said therapeutic compound capable of affecting promoting neurogenesis wherein increased levels of cGMP result in promote neurogenesis.

4. (Currently amended) The neurogenesis affector promoter according to claim 3, wherein said therapeutic compound augments nitric oxide in a tissue.

5. (Currently amended) The neurogenesis affector promoter according to claim 4, wherein said nitric oxide donor is selected from the group consisting essentially of phosphodiesterase inhibitors, L-arginine, sildenafil, and atorvastatin.

6. (Previously presented) A method of augmenting the production of neurons by administering an effective amount of a therapeutic compound that increases levels of cGMP, to a site in need of augmentation, wherein increased levels of cGMP augment the production of neurons.

USSN: 10/075,715
Attorney Docket No.: 1059.00073

7. (Previously presented) A method of increasing neurological function by administering an effective amount of a therapeutic compound that increases levels of cGMP to a patient in need of increased neurological function after neurological damage has occurred, whereby the increased levels of cGMP create neurogenesis, thereby increasing neurological function.

8. (Previously presented) A method of increasing cognitive and neurological function by administering an effective amount of a therapeutic compound for increasing levels of cGMP to a patient in need of increased cognitive and neurological function after neurological and cognitive damage has occurred, whereby the increased levels of cGMP create neurogenesis, thereby increasing neurological function.

9. (Currently amended) A method of affecting promoting neurogenesis comprising the step of administering an effective amount of a compound for increasing levels of cGMP in a patient in need of neurogenesis promotion, wherein increased levels of cGMP result in promote neurogenesis.

10. (Previously presented) A method of augmenting the production of neurons by administering an effective amount of a compound for increasing cGMP levels at a site in need of augmentation, wherein increased levels of cGMP augment the production of neurons.

11. (Previously presented) A method of increasing neurological function by administering an effective amount of a compound for increasing levels of cGMP in a patient in need of increased neurological function, wherein increased levels of cGMP increase neurological function.

12. (Currently amended) A method of increasing cognitive and neurological function by administering an effective amount of a compound for increasing levels of cGMP in a patient in need of increased cognitive and

USSN: 10/075,715
Attorney Docket No.: 1059.00073

neurological function, wherein increased levels of cGMP result in promote neurogenesis, thereby increasing cognitive and neurological function.

13. (Currently amended) A compound for increasing *in vivo* levels cGMP for use in generating neurons, wherein increased levels of cGMP result in promote neurogenesis.